Related Experiment Videos
Photobiomodulation for Alzheimer's Disease: Has the Light Dawned?
Michael R Hamblin1,2,3
1Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA.
Abstract:
Next to cancer, Alzheimer's disease (AD) and dementia is probably the most worrying health problem facing the Western world today. A large number of clinical trials have failed to show any benefit of the tested drugs in stabilizing or reversing the steady decline in cognitive function that is suffered by dementia patients. Although the pathological features of AD consisting of beta-amyloid plaques and tau tangles are well established, considerable debate exists concerning the genetic or lifestyle factors that predispose individuals to developing dementia. Photobiomodulation (PBM) describes the therapeutic use of red or near-infrared light to stimulate healing, relieve pain and inflammation, and prevent tissue from dying. In recent years PBM has been applied for a diverse range of brain disorders, frequently applied in a non-invasive manner by shining light on the head (transcranial PBM). The present review discusses the mechanisms of action of tPBM in the brain, and summarizes studies that have used tPBM to treat animal models of AD. The results of a limited number of clinical trials that have used tPBM to treat patients with AD and dementia are discussed.
Insights
Photobiomodulation (PBM) offers a potential new treatment for Alzheimer's disease (AD) and dementia. Transcranial PBM (tPBM) shows promise in animal models and early human trials for improving cognitive function.
Area of Science:
- Neuroscience
- Biomedical Engineering
- Gerontology
Background:
- Alzheimer's disease (AD) and dementia represent significant health challenges with limited effective treatments.
- Current therapeutic approaches often fail to halt or reverse cognitive decline in patients.
- The underlying causes, including genetic and lifestyle factors, are still debated despite known pathology (amyloid plaques, tau tangles).
Purpose of the Study:
- To review the mechanisms of action for transcranial photobiomodulation (tPBM) in the brain.
- To summarize existing research on tPBM in Alzheimer's disease (AD) animal models.
- To discuss preliminary clinical trial results of tPBM for AD and dementia patients.
Main Methods:
- Literature review of studies on tPBM mechanisms in neurological disorders.
- Analysis of research employing tPBM in animal models of AD.
- Examination of clinical trial data for tPBM in human patients with AD and dementia.
Main Results:
- tPBM utilizes red or near-infrared light for therapeutic effects, including tissue healing and reduced inflammation.
- Studies in AD animal models suggest potential benefits of tPBM.
- Early clinical trials indicate tPBM may be a viable treatment option for AD and dementia, though results are preliminary.
Conclusions:
- Transcranial photobiomodulation (tPBM) presents a novel, non-invasive therapeutic strategy for brain disorders.
- Further research and larger clinical trials are warranted to establish the efficacy of tPBM for Alzheimer's disease and dementia.
- tPBM mechanisms and clinical applications in neurodegenerative diseases require continued investigation.